{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:53:34Z","timestamp":1790996014134,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["GNT2013565"],"award-info":[{"award-number":["GNT2013565"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001785","name":"Flinders University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001785","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11523-024-01124-2","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T12:13:42Z","timestamp":1736252022000},"page":"361-369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tumour Mutational Burden and Immune Checkpoint Inhibitor Response in Non-small Cell Lung Cancer: A Continuous Modelling Approach"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1999-866X","authenticated-orcid":false,"given":"Michael J.","family":"Sorich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6592-5675","authenticated-orcid":false,"given":"Arkady T.","family":"Manning-Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Shahnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganessan","family":"Kichenadasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Karapetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Y.","family":"Abuhelwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"issue":"7549","key":"1124_CR1","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","volume":"332","author":"DG Altman","year":"2006","unstructured":"Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332(7549):1080. https:\/\/doi.org\/10.1136\/bmj.332.7549.1080.","journal-title":"BMJ"},{"issue":"6","key":"1124_CR2","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s43018-022-00382-1","volume":"3","author":"V Anagnostou","year":"2022","unstructured":"Anagnostou V, Bardelli A, Chan TA, Turajlic S. The status of tumor mutational burden and immunotherapy. Nat Cancer. 2022;3(6):652\u20136. https:\/\/doi.org\/10.1038\/s43018-022-00382-1.","journal-title":"Nat Cancer."},{"issue":"13","key":"1124_CR3","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1002\/sim.5639","volume":"32","author":"H Binder","year":"2013","unstructured":"Binder H, Sauerbrei W, Royston P. Comparison between splines and fractional polynomials for multivariable model building with continuous covariates: a simulation study with continuous response. Stat Med. 2013;32(13):2262\u201377. https:\/\/doi.org\/10.1002\/sim.5639.","journal-title":"Stat Med"},{"issue":"19","key":"1124_CR4","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1002\/1097-0258(20001015)19:19","volume":"19","author":"M Bonetti","year":"2000","unstructured":"Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med. 2000;19(19):2595\u2013609. https:\/\/doi.org\/10.1002\/1097-0258(20001015)19:19.","journal-title":"Stat Med"},{"issue":"10","key":"1124_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","volume":"21","author":"J Budczies","year":"2024","unstructured":"Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altb\u00fcrger C, et al. Tumour mutational burden: clinical utility, challenges and emerging improvements. Nat Rev Clin Oncol. 2024;21(10):725\u201342. https:\/\/doi.org\/10.1038\/s41571-024-00932-9.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1124_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251\u201364. https:\/\/doi.org\/10.1016\/j.jmoldx.2014.12.006.","journal-title":"J Mol Diagn"},{"issue":"9","key":"1124_CR7","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","volume":"24","author":"DR Gandara","year":"2018","unstructured":"Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0134-3.","journal-title":"Nat Med"},{"key":"1124_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis","author":"FE Harrell Jr","year":"2015","unstructured":"Harrell FE Jr. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. 2nd ed. Cham: Springer; 2015.","edition":"2"},{"issue":"12","key":"1124_CR9","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1001\/jamaoncol.2023.3996","volume":"9","author":"AM Hopkins","year":"2023","unstructured":"Hopkins AM, Modi ND, Abuhelwa AY, Kichenadasse G, Kuderer NM, Lyman GH, et al. Heterogeneity and utility of pharmaceutical company sharing of individual-participant data packages. JAMA Oncol. 2023;9(12):1621\u20136. https:\/\/doi.org\/10.1001\/jamaoncol.2023.3996.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1124_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005801","volume":"11","author":"RSP Huang","year":"2023","unstructured":"Huang RSP, Carbone DP, Li G, Schrock A, Graf RP, Zhang L, et al. Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis. J Immunother Cancer. 2023;11(1): e005801. https:\/\/doi.org\/10.1136\/jitc-2022-005801.","journal-title":"J Immunother Cancer"},{"issue":"17","key":"1124_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1158\/1078-0432.Ccr-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res. 2021;27(17):685\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-0327.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1124_CR12","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2022.2867","volume":"8","author":"ND Modi","year":"2022","unstructured":"Modi ND, Abuhelwa AY, McKinnon RA, Boddy AV, Haseloff M, Wiese MD, et al. Audit of data sharing by pharmaceutical companies for anticancer medicines approved by the US Food and Drug Administration. JAMA Oncol. 2022;8(9):1310\u20136. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2867.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1124_CR13","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/s41591-022-01933-w","volume":"28","author":"S Peters","year":"2022","unstructured":"Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med. 2022;28(9):1831\u20139. https:\/\/doi.org\/10.1038\/s41591-022-01933-w.","journal-title":"Nat Med"},{"issue":"8","key":"1124_CR14","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","volume":"8","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 2022;8(8):1160\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1981.","journal-title":"JAMA Oncol"},{"key":"1124_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072883","volume":"379","author":"RD Riley","year":"2022","unstructured":"Riley RD, Cole TJ, Deeks J, Kirkham JJ, Morris J, Perera R, et al. On the 12th day of Christmas, a statistician sent to me. BMJ. 2022;379: e072883. https:\/\/doi.org\/10.1136\/bmj-2022-072883.","journal-title":"BMJ"},{"issue":"15","key":"1124_CR16","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/sim.8516","volume":"39","author":"RD Riley","year":"2020","unstructured":"Riley RD, Debray TPA, Fisher D, Hattle M, Marlin N, Hoogland J, et al. Individual participant data meta-analysis to examine interactions between treatment effect and participant-level covariates: statistical recommendations for conduct and planning. Stat Med. 2020;39(15):2115\u201337. https:\/\/doi.org\/10.1002\/sim.8516.","journal-title":"Stat Med"},{"issue":"5","key":"1124_CR17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","volume":"6","author":"NA Rizvi","year":"2020","unstructured":"Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn M-J, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 2020;6(5):661\u201374. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0237.","journal-title":"JAMA Oncol"},{"issue":"16","key":"1124_CR18","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/sim.1815","volume":"23","author":"P Royston","year":"2024","unstructured":"Royston P, Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med. 2024;23(16):2509\u201325. https:\/\/doi.org\/10.1002\/sim.1815.","journal-title":"Stat Med"},{"issue":"1","key":"1124_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12874-022-01516-w","volume":"22","author":"W Sauerbrei","year":"2022","unstructured":"Sauerbrei W, Royston P. Investigating treatment-effect modification by a continuous covariate in IPD meta-analysis: an approach using fractional polynomials. BMC Med Res Methodol. 2022;22(1):98. https:\/\/doi.org\/10.1186\/s12874-022-01516-w.","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"1124_CR20","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1016\/j.csda.2006.12.041","volume":"51","author":"W Sauerbrei","year":"2007","unstructured":"Sauerbrei W, Royston P, Zapien K. Detecting an interaction between treatment and a continuous covariate: a comparison of two approaches. Comput Stat Data Anal. 2007;51(8):4054\u201363. https:\/\/doi.org\/10.1016\/j.csda.2006.12.041.","journal-title":"Comput Stat Data Anal"},{"issue":"6","key":"1124_CR21","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1158\/1078-0432.Ccr-20-3771","volume":"27","author":"H Si","year":"2021","unstructured":"Si H, Kuziora M, Quinn KJ, Helman E, Ye J, Liu F, et al. A blood-based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment: results from the MYSTIC Study. Clin Cancer Res. 2021;27(6):1631\u201340. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-3771.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1124_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s43856-023-00243-7","volume":"3","author":"SA Tomlins","year":"2023","unstructured":"Tomlins SA, Khazanov NA, Bulen BJ, Hovelson DH, Shreve MJ, Lamb LE, et al. Development and validation of an integrative pan-solid tumor predictor of PD-1\/PD-L1 blockade benefit. Commun Med (Lond). 2023;3(1):14. https:\/\/doi.org\/10.1038\/s43856-023-00243-7.","journal-title":"Commun Med (Lond)."},{"issue":"1","key":"1124_CR23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","volume":"12","author":"C Valero","year":"2021","unstructured":"Valero C, Lee M, Hoen D, Weiss K, Kelly DW, Adusumilli PS, et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021;12(1):729. https:\/\/doi.org\/10.1038\/s41467-021-20935-9.","journal-title":"Nat Commun"},{"issue":"1","key":"1124_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/1467-9868.00374","volume":"65","author":"SN Wood","year":"2003","unstructured":"Wood SN. Thin plate regression splines. J R Stat Soc Ser B. 2003;65(1):95\u2013114. https:\/\/doi.org\/10.1111\/1467-9868.00374.","journal-title":"J R Stat Soc Ser B"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01124-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01124-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01124-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T22:00:33Z","timestamp":1743026433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01124-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1124"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01124-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"18 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. The project was supported by a research grant (GNT2013565) from Australia\u2019s National Health and Medical Research Council (NHMRC). Michael J. Sorich is supported by a Beat Cancer Principal Research Fellowship from the Cancer Council of South Australia. Ashley M. Hopkins is supported by an NHMRC Investigator Fellowship (APP2008119), with additional funding from the Hospital Research Foundation and Tour De Cure. Ross A. McKinnon was funded by the Cancer Council of South Australia on a Beat Cancer Professional Fellowship during this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Michael J. Sorich and Ross A. McKinnon receive research funding from Pfizer, unrelated to the current work. Andrew Rowland declares investigator-initiated grant funding for projects unrelated to this work from AstraZeneca, Boehringer Ingelheim and Pfizer Inc. Andrew Rowland declares speaker payments from Boehringer Ingelheim and Genentech. Christos S. Karapetis holds an advisory board role with Roche, BMS, AstraZeneca, Merck and Beigene. Arkady T. Manning-Bennett, Lee X. Li, Adel Shahnam,\u00a0Ganessan Kichenadasse, Ahmad Y. Abuhelwa and Ashley M. Hopkins have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All clinical trials used in the analyses were performed in accordance with the Declaration of Helsinki. The secondary analysis of anonymised patient data was deemed as minimal risk research by the Southern Adelaide Local Health Network, Officer for Research and Ethics, and was exempted from review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Patient consent was affirmed in each of the aforementioned trials.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors have given their consent for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All TMB and clinical data for all cohorts in this study were accessed and are publicly available via their original publications [\n                      \n                      ,\n                      \n                      \u2013\n                      \n                      ].","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualisation was performed by MJS. Study methodology and formal analysis were performed by MJS, ATM-B, LXL and AMH, with validation performed by MJS and LXL. Investigation was performed by MJS, ATM-B, AS, GK, CSK, RAM, AYA AR and AMH. The first draft of the manuscript was written by MJS, AM-B and AMH and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Supervision was performed by MJS and AMH.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}